Joint Disease Clinical Trial
Official title:
Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components
Verified date | November 2023 |
Source | MicroPort Orthopedics Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.
Status | Enrolling by invitation |
Enrollment | 143 |
Est. completion date | December 2032 |
Est. primary completion date | December 2032 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: To be included in the study, subjects must meet all of the following criteria: - Has previously undergone primary Total Hip Arthroscopy for any of the following: - Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; - Inflammatory degenerative joint disease such as rheumatoid arthritis; - Correction of functional deformity - Subject was implanted with the specified combination of components, namely, any MicroPort Orthopedics or Wright Medical Technology femoral stem and PROCOTYL C Acetabular Components - Subject is willing and able to complete required study visits or assessments Previously implanted bilateral subjects can have both THAs (Total Hip Arthroscopy) enrolled in the study provided: 1. the specified combination of components were implanted in both, 2. all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4. the subject agrees to a second Informed Consent document specific to the second THA. Prospective enrolment of a previously unimplanted hip is not permitted in this study. Exclusion Criteria: Subjects will be excluded if they meet any of the following criteria: - Subject was skeletally immature (less than 21 years of age) at time of implantation - Subject has a non-MicroPort or non-Wright Medical Technology component implanted (femoral heads, acetabular shells, acetabular liners) in the enrolled Total Hip Arthroscopy - Subject is currently enrolled in another clinical investigation which could affect the endpoints of this protocol - Subject is unwilling or unable to sign the Informed Consent document - Subject has documented substance abuse issues - Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study - Subject is currently incarcerated or has impending incarceration |
Country | Name | City | State |
---|---|---|---|
Germany | Elbe Kliniken Buxtehude | Buxtehude |
Lead Sponsor | Collaborator |
---|---|
MicroPort Orthopedics Inc. |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Component Survivorship | The primary endpoint is to evaluate component survivorship of the PROCOTYL® C Acetabular Components out to 10 years follow-up. Percentage of hips survived with no revision or replacement at 10-year. | 10 years post-operative | |
Secondary | To determine the cumulative incidence of component revision at specified intervals out to 10 years follow-up; | Percentage of hips that were revised or replaced at each of the intervals namely for Early (2-5 years), midterm (5-7 Year), and long-term (10-year) evaluation. | 2-5 years, 5-7 years, and 10 years | |
Secondary | To characterize functional scores, as assessed by Oxford Hip. | The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'. | 2-5 years, 5-7 years, and 10 years | |
Secondary | To characterize functional scores, as assessed by EQ-5D-3L scores. | EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems. | 2-5 years, 5-7 years, and 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02314702 -
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems
|
||
Completed |
NCT03271151 -
Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT03272139 -
Interscalene Block Versus Superior Trunk Block
|
Phase 4 | |
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT01256216 -
Signature Versus Computer Assisted Surgery Study
|
N/A | |
Completed |
NCT03337243 -
Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis
|
N/A | |
Active, not recruiting |
NCT03294408 -
Multimodal Imaging of Subchondral Bone in Knee Osteoarthritis : Predictive Model
|
N/A | |
Withdrawn |
NCT02668211 -
Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components
|
N/A | |
Active, not recruiting |
NCT02239783 -
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems
|
||
Terminated |
NCT00698347 -
A Clinical Investigation of the M2a-Magnumâ„¢ Hip System
|
N/A | |
Completed |
NCT00223353 -
Quantitative Gait Analysis for Clinical Decision Making
|
N/A | |
Recruiting |
NCT04037735 -
RSA-RCT: Attune S+ TKA Versus Sigma TKA
|
N/A | |
Terminated |
NCT03575975 -
3D X-ray Motion Analysis of Ankle-foot Motion After Total Ankle Arthroplasty
|
||
Completed |
NCT03894514 -
Multi-variable Prediction Model of Total Knee Replacement Outcome
|
||
Completed |
NCT02865447 -
Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis
|
||
Completed |
NCT02967874 -
Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT02390336 -
Mobilization With Movement in Patients With Osteoarthritis of the Hip
|
N/A | |
Terminated |
NCT03293719 -
Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic
|
||
Active, not recruiting |
NCT02823834 -
PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components
|
||
Active, not recruiting |
NCT02351414 -
Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts
|